Timothy A. Springer net worth and biography

Timothy Springer Biography and Net Worth

Director of Tectonic Therapeutic

Tim is an immunologist and biophysicist serving as Latham Family Professor at Harvard Medical School and Boston Children’s Hospital, and a co-founder of Tectonic. He discovered integrins and their ligands in the 1980s, and this work enabled the discovery of novel treatments for autoimmune diseases including Amevive^®, Raptiva^®, Campath^®, Velcade^®, and Entyvio^®. Tim is also the founder of the Institute for Protein Innovation. He is a highly successful serial entrepreneur and has been the founder and/or founding investor of multiple biotechnology companies (Morphic Therapeutic, Editas Medicine, Scholar Rock, Moderna, LeukoSite). Tim is a member of the National Academy of Sciences and his honors include the Crafoord Prize, The American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, the Basic Research Prize from the American Heart Association, and the 2022 Lasker Award. He received his Ph.D. from Harvard University.

What is Timothy A. Springer's net worth?: The estimated net worth of Timothy A. Springer is at least $90.58 million as of April 9th, 2025. Springer owns 4,317,276 shares of Tectonic Therapeutic stock worth more than $90,576,450 as of December 5th. This net worth estimate does not reflect any other investments that Springer may own. Learn More about Timothy A. Springer's net worth.
How do I contact Timothy A. Springer?: The corporate mailing address for Springer and other Tectonic Therapeutic executives is 100 TECHNOLOGY SQUARE 6TH FLOOR, CAMBRIDGE MA, 02139. Tectonic Therapeutic can also be reached via phone at 617-914-8420 and via email at [email protected]. Learn More on Timothy A. Springer's contact information.
Has Timothy A. Springer been buying or selling shares of Tectonic Therapeutic?: Timothy A. Springer has not been actively trading shares of Tectonic Therapeutic during the last ninety days. Most recently, on Friday, April 11th, Timothy A. Springer bought 9,478 shares of Tectonic Therapeutic stock. The stock was acquired at an average cost of $16.31 per share, with a total value of $154,586.18. Following the completion of the transaction, the director now directly owns 4,334,846 shares of the company's stock, valued at $70,701,338.26. Learn More on Timothy A. Springer's trading history.
Who are Tectonic Therapeutic's active insiders?: Tectonic Therapeutic's insider roster includes Daniel Lochner (CFO), and Timothy Springer (Director). Learn More on Tectonic Therapeutic's active insiders.
Are insiders buying or selling shares of Tectonic Therapeutic?: In the last year, Tectonic Therapeutic insiders bought shares 5 times. They purchased a total of 234,607 shares worth more than $8,955,655.40. The most recent insider tranaction occured on April, 11th when Director Timothy A Springer bought 9,478 shares worth more than $154,586.18. Insiders at Tectonic Therapeutic own 38.0% of the company. Learn More about insider trades at Tectonic Therapeutic.
Information on this page was last updated on 4/11/2025.

Timothy A. Springer Insider Trading History at Tectonic Therapeutic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/11/2025	Buy	9,478	$16.31	$154,586.18	4,334,846
4/9/2025	Buy	3,718	$14.76	$54,877.68	4,317,276
4/7/2025	Buy	87,500	$17.10	$1,496,250.00	4,313,558
2/5/2025	Buy	129,294	$54.14	$6,999,977.16	4,226,058
10/22/2024	Buy	300,000	$33.59	$10,077,000.00	4,096,764
9/26/2024	Buy	50,000	$28.82	$1,441,000.00	3,796,764

Timothy A. Springer Buying and Selling Activity at Tectonic Therapeutic

Tectonic Therapeutic Company Overview

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Today's Range

Now: $20.98

$19.56

$21.50

50 Day Range

MA: $17.95

$14.91

$21.47

2 Week Range

Now: $20.98

$13.70

$61.07

Volume

290,375 shs

Average Volume

401,310 shs

Market Capitalization

$392.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.65